Protalix BioTherapeutics, Inc | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (77)

Latest Posts

About This Stock More About This Stock
Pullix Gains Momentum As Gamestop Exits NFT Space
Article By: Invezz
Sunday, January 14, 2024 9:30 AM EDT
Notable NFT news this week is from video game retailer GameStop, which has announced its NFT marketplace will shut down next month. The publicly-traded company is citing “regulatory uncertainty” for its decision to discontinue the NFT business.
In this article: GME, PLX
Read
Protalix BioTherapeutics Well Placed To Advance In 2023
Article By: Shareholders Unite
Monday, December 12, 2022 12:47 PM EDT
We see a number of reasons to be positive about PLX shares in 2023 and investors should take note.
In this article: PLX, PFE
Read
Protalix PRX-102: Likely Approval Could Be A Game Changer
Article By: Shareholders Unite
Monday, May 2, 2022 9:02 AM EDT
Protalix's PRX-102 drug stands a good chance of being accepted against Fabry disease, with three P3 trials delivering good results.
In this article: PLX Also: PFE
Read
Why Protalix Is Back On The Radar
Article By: Kate Hayden
Tuesday, April 19, 2022 8:55 AM EDT
After encountering bureaucratic hurdles, Protalix's PRX-102 has come through the BALANCE study with flying colors and is ready to reapply for its BLA.
In this article: PLX
Read
Protalix BioTherapeutics: Management Sounds Confident Despite CRL
Article By: Avisol Capital Partners
Wednesday, January 5, 2022 9:39 AM EDT
A spate of bad bureacratic luck - including the FDA letter explaining that Covid kept them from doing an inspection - has put PLX's Fabry disease drug in an uncompetitive position, but we reached out to management to learn more about the pipeline.
In this article: PLX
Read

Latest Tweets for $PLX

No tweets yet!

PARTNER HEADLINES

$PLX

Protalix BioTherapeutics Well Placed to Advance in 2023
Stock Profit 12/13/2022 9:25:29 AM

Maybe as a p4 trial they could perform a small scale fresh ERT head 2 head? I think that would be super compelling for prescribers! 
 
I also still have wondered about the once a month dosing protocol. Like every article says "may be able to do that" but what does the data say for the once monthly dosing? Was the drug effective enough? Is there NDA/EMA submissions gunning for a once a month dose protocol in labeling discussions? My guess is not as they wanna stay conservative for initial approval then work towards getting additional labelings down the road for once a month... guess time will tell but if the once a month dosing comes to fruition thats a huge advantage too. 

I'm bullish on $PLX.

Protalix BioTherapeutics Well Placed to Advance in 2023
Harry Goldstein 12/13/2022 12:08:08 AM

I read your last article on $PLX as well which was equally impressive.  Sounds like the company has a promising 2023 to look forward too!

Protalix PRX-102: Likely Approval Could Be A Game Changer
Wall St. Wolf 5/29/2022 3:25:16 PM

Sounds very promising.  Just picked up some $PLX.

Why Protalix Is Back On The Radar
Kurt Benson 4/20/2022 10:43:37 AM

Bullish on $PLX.

Why Protalix Is Back On The Radar
Terrence Howard 4/19/2022 2:33:49 PM

$PLX has been on my radar for a while. Ever since Moon Kil Woong first wrote abuot it. I believe the stock shows tremendous promise and is quite affordable.

Protalix BioTherapeutics: Management Sounds Confident Despite CRL
Adam Reynolds 1/8/2022 7:57:42 PM

Seems like the CLR was completely unfair since it was the FDA that was unable to do the inspection.  That should not reflect negatively on $PLX at all.

Protalix BioTherapeutics: Management Sounds Confident Despite CRL
Terrence Howard 12/30/2021 4:58:14 PM

Good read, thanks.  Moon Kil Woong, you've often covered $PLX.  What's your take?

PLX Upcoming Volatility Creates Opportunity
IB Trading 7/27/2021 11:35:05 PM

Had our eyes on $PLX for a while now. I think big things are coming for this company.

1 to 10 of 21 comments